Biomedical firm with Marlborough location hires new CEO
Image | Courtesy of StageBio
David Bruning, CEO of StageBio
StageBio, a Virginia-based firm with a location in Marlborough providing services and equipment to companies involved in preclinical and clinical research, has hired David Bruning as its CEO.
Bruning, who has served on StageBio’s board of directors for the previous five years, has more than 25 years of experience with companies providing preclinical testing services, according to a press release issued by the company on Monday. Bruning’s prior experience includes stints at Maryland-based analytical testing firm BioReliance and California-based biotech firm Life Technologies.
"I'm grateful for the opportunity to lead StageBio in its next phase of growth,” Bruning said in the release. “We have a talented and innovative team across our sites in North America and Europe dedicated to delivering superior service and scientific rigor to our customers throughout the biopharmaceutical, medical device, and contract research industries.”
The company opened its 10,000-square-foot Marlborough laboratory in August 2020. Founder and then-CEO Tom Galati told WBJ at the time that the company opened the facility to meet the demand for molecular pathology services in the region.
Galati left the company in January 2022, according to his LinkedIn page.
StageBio operates eight facilities in the United States and one in Germany. The company is backed by Ampersand Capital Partners, a Wellesley-based private equity firm.
WBJ Web Partners
Most Recent
Most Recent
0 Comments